Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.57 |
| ▸ | IDO1 | P14902 | 5/20 | 0.53 |
| ▸ | MAOB | P27338 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | AGXT | P21549 | 2/20 | 0.47 |
| ▸ | KIF11 | P52732 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9371761 | 0.98 | TAAR1 (0.55) | TAAR1IDO1MAOBALDH1A1SMN1; SMN2 | |
| SCHEMBL728403 | 0.84 | IDO1 (0.56) | TAAR1IDO1MAOBALDH1A1SMN1; SMN2 | |
| SCHEMBL62037 | 0.83 | IDO1 (0.59) | TAAR1IDO1MAOBALDH1A1SMN1; SMN2 | |
| SCHEMBL6511578 | 0.83 | TAAR1 (0.47) | TAAR1IDO1MAOBALDH1A1SMN1; SMN2 | |
| SCHEMBL27715704 | 0.83 | TAAR1 (0.47) | TAAR1IDO1MAOBALDH1A1SMN1; SMN2 | |
| SCHEMBL11573046 | 0.81 | NQO1 (0.50) | ALDH1A1SMN1; SMN2KIF11TSHRALOX12 | |
| Hydrochloric Acid SCHEMBL5797813 | 0.81 | IDO1 (0.60) | TAAR1IDO1MAOBALDH1A1SMN1; SMN2 | |
| SCHEMBL6624910 | 0.81 | IDO1 (0.57) | TAAR1IDO1MAOBALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11119737 | 0.81 | CYP2C19 (0.48) | IDO1CYP3A4 | |
| SCHEMBL8841051 | 0.81 | IDO1 (0.49) | TAAR1IDO1MAOBALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170115259-A1 | HIGH PERFORMANCE LIQUID CHROMATOGRAPHY METHOD FOR ANALYZING IMAGING AGENT, PRECURSOR OF IMAGING AGENT, OR INTERMEDIATE OF IMAGING AGENT | Institute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan, R.O.C. (TW) | 2017-04-27 | — | — | US | claimed |
| US-20250319213-A1 | FUNCTIONALIZED BISAMINOTHIOL DERIVATIVES, COMPLEXES WITH THESE BISAMINOTHIOL DERIVATIVES AND USE OF SAID COMPLEXES AS DIAGNOSTICS AND THERAPEUTICS | ABX ADVANCED BIOCHEMICAL COMPOUNDS – BIOMEDIZINISCHE FORSCHUNGSREAGENZIEN GMBH (DE) | 2025-10-16 | — | — | US | disclosed |
| EP-4529473-A1 | FUNCTIONALIZED BISAMINOTHIOL DERIVATIVES, COMPLEXES WITH THESE BISAMINOTHIOL DERIVATIVES AND USE OF SAID COMPLEXES AS DIAGNOSTICS AND THERAPEUTICS | ABX Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien GmbH (DE) | 2025-04-02 | — | — | EP | disclosed |
| WO-2023227535-A1 | FUNCTIONALIZED BISAMINOTHIOL DERIVATIVES, COMPLEXES WITH THESE BISAMINOTHIOL DERIVATIVES AND USE OF SAID COMPLEXES AS DIAGNOSTICS AND THERAPEUTICS | ABX ADVANCED BIOCHEMICAL COMPOUNDS GMBH (DE) | 2023-11-30 | — | — | WO | disclosed |
| EP-4282438-A1 | FUNCTIONALIZED BISAMINOTHIOL DERIVATIVES, COMPLEXES WITH THESE BISAMINOTHIOL DERIVATIVES AND USE OF SAID COMPLEXES AS DIAGNOSTICS AND THERAPEUTICS | ABX Advanced Biochemical Compounds GmbH (DE) | 2023-11-29 | — | — | EP | disclosed |
| US-20170115259-A1 | HIGH PERFORMANCE LIQUID CHROMATOGRAPHY METHOD FOR ANALYZING IMAGING AGENT, PRECURSOR OF IMAGING AGENT, OR INTERMEDIATE OF IMAGING AGENT | Institute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan, R.O.C. (TW) | 2017-04-27 | — | — | US | disclosed |
| US-20170115259-A1 | HIGH PERFORMANCE LIQUID CHROMATOGRAPHY METHOD FOR ANALYZING IMAGING AGENT, PRECURSOR OF IMAGING AGENT, OR INTERMEDIATE OF IMAGING AGENT | Institute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan, R.O.C. (TW) | 2017-04-27 | — | — | US | disclosed |
| US-8889691-B2 | Indole compounds as an inhibitor of cellular necrosis | LG LIFE SCIENCES LTD. (KR) | 2014-11-18 | — | — | US | disclosed |
| US-20140024618-A1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2014-01-23 | — | — | US | disclosed |
| US-8569307-B2 | Indole compounds as an inhibitor of cellular necrosis | LG LIFE SCIENCES LTD. (KR) | 2013-10-29 | — | — | US | disclosed |
| EP-0302366-B1 | Substituted pyridine derivatives | BAYER AG (DE) | 1994-09-14 | — | — | EP | disclosed |
| US-5103018-A | Antitumor agent; side effect reduction | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1992-04-07 | — | — | US | disclosed |
| EP-0302366-A2 | Substituted pyridine derivatives | BAYER AG (DE) | 1989-02-08 | — | — | EP | disclosed |
| EP-0280741-A1 | MITOMYCIN DERIVATIVES | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1988-09-07 | — | — | EP | disclosed |
| US-4496567-A | HSITAMINE H2 ANTAGONISTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-01-29 | — | — | US | disclosed |
| EP-0013071-B1 | PYRIMIDINONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1983-11-16 | — | — | EP | disclosed |
| US-4322342-A | Analgesic compounds | ELI LILLY AND COMPANY (US) | 1982-03-30 | — | — | US | disclosed |
| US-4259234-A | OLIGOPEPTIDES FOR PARENTERAL ADMINISTRATION | ELI LILLY AND COMPANY (US) | 1981-03-31 | — | — | US | disclosed |
| EP-0013071-A1 | Pyrimidinone derivatives, processes for preparing them and pharmaceutical compositions containing them | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-07-09 | — | — | EP | disclosed |
| WO-1980000966-A1 | NEW HISTAMINE H2-ANTAGONISTS | SMITH KLINE FRENCH LAB (GB) | 1980-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024618-A1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | IDO1, IDO2, TNF | TAAR1 1020/4885IDO1 1/4885MAOB 86/4885 |
| US-20250319213-A1 | FUNCTIONALIZED BISAMINOTHIOL DERIVATIVES, COMPLEXES WITH THESE BISAMINOTHIOL DERIVATIVES AND USE OF SAID COMPLEXES AS DIAGNOSTICS AND THERAPEUTICS | MARS1, MARS2, BCAT1 | TAAR1 1752/4885IDO1 1647/4885MAOB 2312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.